Substitution of amino acids 70 and 91 in the hepatitis C virus (HCV) core region is a significant predictor of poor responses to peginterferon-plus-ribavirin therapy, while their molecular mechanisms remain unclear. Here we investigated these differences in the response to alpha interferon (IFN) by using HCV cell culture with R70Q, R70H, and L91M substitutions. IFN treatment of cells transfected or infected with the wild type or the mutant HCV clones showed that the R70Q, R70H, and L91M core mutants were significantly more resistant than the wild type. Among HCV-transfected cells, intracellular HCV RNA levels were significantly higher for the core mutants than for the wild type, while HCV RNA in culture supernatant was significantly lower for these mutants than for the wild type. IFN-induced phosphorylation of STAT1 and STAT2 and expression of the interferon-inducible genes were significantly lower for the core mutants than for the wild type, suggesting cellular unresponsiveness to IFN. The expression level of an interferon signal attenuator, SOCS3, was significantly higher for the R70Q, R70H, and L91M mutants than for the wild type. Interleukin 6 (IL-6), which upregulates SOCS3, was significantly higher for the R70Q, R70H, and L91M mutants than for the wild type, suggesting interferon resistance, possibly through IL-6-induced, SOCS3-mediated suppression of interferon signaling. Expression levels of endoplasmic reticulum (ER) stress proteins were significantly higher in cells transfected with a core mutant than in those transfected with the wild type. In conclusion, HCV R70 and L91 core mutants were resistant to interferon in vitro, and the resistance may be induced by IL-6-induced upregulation of SOCS3. Those mechanisms may explain clinical interferon resistance of HCV core mutants.
Hepatitis C virus (HCV) is one of the most important pathogens causing liver-related morbidity and mortality. Approximately 3% of the worldwide population is infected with HCV, which represents 170 million people, and 3 million to 4 million individuals are newly infected each year (33, 47, 62) . There is no therapeutic or prophylactic vaccine available for HCV. Antiviral treatment has been shown to improve liver histology and decrease the incidence of hepatocellular carcinoma in chronic hepatitis C (CHC) (17, 64) . Current therapies for CHC consist of treatment with pegylated interferon (peg-IFN), which acts both as an antiviral and as an immunoregulatory cytokine, and ribavirin (RBV), an antiviral prodrug that interferes with RNA metabolism (16, 31) . However, less than 50% of patients infected with HCV genotype 1 treated in this way achieve a sustained virological response (SVR) or a cure of the infection (14, 16) . Given this situations, gaining a detailed understanding of the molecular mechanisms of interferon (IFN) resistance has been a high priority in academia and industry.
The response to peg-IFN-plus-RBV treatment is affected by several viral and host factors, including age, gender (22, 23) , grade of liver fibrosis (21, 42) , HCV genotype, and serum viral load (14, 59) . Several viral genetic factors influence treatment outcomes, including mutations in NS5A-interferon sensitivity determining region (ISDR) (13, 38) and the core region (4, 6). Akuta et al. reported that HCV-core amino acid substitutions at positions 70 and 91 are significantly correlated with poor responses to peg-IFN-plus-RBV therapy (6) and with increased hepatocarcinogenesis (2, 3) . Furthermore, it was reported recently that the core amino acid 70 and amino acid 91 substitutions are associated with a poor response to peg-IFN, RBV, and telaprevir combination therapy, respectively (1) . However, the underlying molecular mechanisms of such distinct biological properties of the core 70/91 mutations are poorly understood. In this study, we have analyzed virus infection and replication kinetics and response to interferon treatment using the HCV-JFH1 cell culture system (HCVcc) (60, 65) . We constructed HCVcc expressing virus with substitutions of core amino acid 70 and amino acid 91 (R70Q, R70H, and L91M). The core mutant HCV clones were compared in terms of intracellular replication, infectious virus production, and sensitivity to alpha interferon (IFN-␣). Here we have shown that the differences in sensitivity to IFN are attributable to upregulated overexpression of the cellular interferon signal attenuator SOCS3 and that this upregulation is caused by overexpression of interleukin-6 (IL-6).
Immunohistochemistry. HCV-transfected Huh7 cells were cultured on 18-mm round micro cover glasses (Matsunami, Tokyo, Japan). For detection of HCV core, lipid droplet, and endoplasmic reticulum (ER), cells were fixed with cold acetone for 15 min. The cells were incubated with the primary antibodies for 1 h at 37°C. The fluorescent secondary antibodies were Alexa 405 goat anti-mouse and 568 donkey anti-rabbit IgG antibodies (Invitrogen, Carlsbad, CA). Lipid droplets (LDs) were visualized by using Bodipy 493/503 dye (Invitrogen). Cells were mounted with Vecta Shield mounting medium and 4Ј,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA) and visualized by using a confocal laser scanning microscope (FV10i; Olympus, Tokyo, Japan).
Calculation of 50% effective concentrations (EC 50 ). The EC 50 was calculated as the concentration of IFN required for 50% reduction in HCV RNA expression. We used the probit regression analysis to obtain values.
Statistical analyses. Statistical analyses were performed by using Welch's t test. P values of less than 0.05 were considered statistically significant.
RESULTS
HCV core 70/91 mutants show resistance to IFN treatment. First, we investigated sensitivity to IFN treatment of the HCV core mutant R70Q, R70H, and L91M virus clones and compared them to the wild type. The wild type and core mutants were transfected into Huh7 cells, which were cultured in the presence of various concentrations of IFN-␣ for 48 h. RNA was extracted from the cells and culture supernatant, and the level of HCV RNA was quantified by real-time RT-PCR. Although the levels of supernatant HCV RNA did not differ between the wild type and core mutants (Fig. 1A) , the levels of cellular HCV RNA showed that all three core mutants were significantly resistant to IFN compared to the wild type, with EC 50 s of 5.0 IU/ml, 48 IU/ml, 32 IU/ml, and 47 IU/ml for the R70Q, R70H, L91M, and mutants and the wild type, respectively (Fig. 1B) . To exclude the possible effects on interferon signaling by the input HCV RNA, we performed interferon sensitivity analyses by HCVcc infection. As shown in Fig.  1C , the interferon sensitivities of HCV core mutants and the wild type were consistent with the results of HCV RNA transfection. Similarly, according to Western blotting, the core mutants were more resistant to IFN treatment than the wild type (Fig. 1D) .
Core mutants show decreased secretion of viral particles. To determine the mechanisms underlying the resistance to interferon, we compared baseline virus expression levels in cells and culture supernatants. The three core mutants, carrying R70Q, R70H, and L91M, expressed significantly higher levels of intracellular HCV RNA than the wild type, as well as the 7780K clone. (Fig. 2A) . 7780K was a negative-control clone that lacked virus particle secretion (37) . On the contrary, these core mutants released significantly smaller amounts of HCV RNA into the culture supernatant than the wild type, as well as the negative-control 7780K clone. (Fig. 2B) . Consistent with the HCV RNA data, Western blotting showed that cellular HCV core protein levels were higher for the core amino acid 70/91 mutants than the wild type (Fig. 2C) . These results suggested that the core 70/91 mutant clones were partially defective in the secretion of infectious virus particles.
Subcellular localization of wild-type and mutant core proteins and lipid droplets. It has been reported that HCV core protein localizes on the cellular LD membrane and may mediate encapsidation of viral genomic RNA and subsequent virus assembly (35, 36) . Therefore, we visualized the subcellular localization of wild-type and mutant core proteins in rela- tion to that of LDs and the ER by indirect immunofluorescence and confocal microscopy. Consistent with previous reports, core proteins were colocalized with LDs but not with an ER-located protein, PDI, in the HCV-transfected cells (see the figure in the supplemental material). There were no obvious differences in colocalization of core and LDs or core and ER between the wild type and mutant core proteins. Induction of interferon-stimulated genes following treatment of HCV-transfected cells with interferon. To investigate the mechanism of the relative IFN resistance of the core 70/91 mutants, as demonstrated in Fig. 1 , we analyzed the cellular IFN signaling pathway. First, we assessed the expression and IFN-mediated induction of the mRNA transcripts of the IFNstimulated genes (ISGs), encoding P56, double-stranded RNA-dependent protein kinase R (PKR), and 2Ј,5Ј-oligoadenylate synthetase (25AS), which mediate direct antiviral effects on HCV expression (24, 25) . Cellular expression of PKR, P56, and 25AS was substantially increased in HCVtransfected cells, as well as naive cells, following IFN treatment. However, the levels of induction were significantly lower in the three HCV core mutant-transfected cells than in wildtype-transfected cells (Fig. 3A , B, and C). We next detected IFN-induced phosphorylation of STAT1 and STAT2 in the mutant and wild-type HCV-expressing cells. Our previous experiments showed that the levels of phosphorylated STAT1 and STAT2 (pSTAT1 and pSTAT2, respectively) increased within minutes of the addition of IFN and decreased subsequently at 8 h (25) . Therefore, we detected pSTAT1 and pSTAT2 levels before and at 15 min after the addition of IFN. As shown in Fig. 3D and E, levels of pSTAT1 and pSTAT2 were lower in core mutant-transfected and -infected cells after IFN treatment than in wild-type-transfected cells and naive cells. These findings indicate that the differences in sensitivity to interferon of core mutant clones and the wild type were associated with attenuation of the cellular IFN signaling pathway.
SOCS3 is upregulated in core mutant clones-transfected, IFN-resistant cells. We examined next the effects of HCV replication on the expression of SOCS1 and SOCS3, proteins that suppress IFN receptor-mediated signaling (50, 58) . There was no significant difference in expression levels of SOCS1 mRNA between cells transfected with the wild type and the core mutant clones. In contrast, the SOCS3 mRNA expression level was significantly higher in core mutant-transfected cells than in wild-type-transfected cells (Fig. 4A and B) . It is known that SOCS3 is induced principally by phosphorylated STAT3 (pSTAT3) (18) and that interleukin-6 (IL-6) is a strong inducer of pSTAT3 via receptor-mediated Janus kinase activation in the liver (41, 51) . On that basis, we investigated whether overexpression of SOCS3 is associated with increased pSTAT3 and with overproduction of IL-6. The pSTAT3 level was significantly higher in core mutant-transfected cells than in JFH1-transfected cells and naive Huh7 cells (Fig. 5A) . Moreover, cellular IL-6 mRNA expression was significantly higher in core mutant-transfected cells than in wild-type-transfected cells (Fig. 5B) . These findings suggested that upregulation of cellular SOCS3 is associated with the resistance to IFN of the core 70/91 mutant HCV clones and that this effect is mediated partly by overproduction of IL-6.
UPRs are enhanced in core mutant-transfected cells. We have reported that HCV causes direct cytopathic effects on host cells and that these effects are mediated by HCV-induced unfolded protein responses (UPRs) (48) . Therefore, we detected the expression of UPR-related proteins, GRP78 and CHOP, in cells expressing wild-type HCV and the core 70/91 mutants. As shown in Fig. 6 , HCV-transfected cells showed higher expression levels of GRP78 and CHOP than untransfected cells. Furthermore, cells transfected with HCV core 70/91 mutant clones expressed larger amounts of GRP78 and CHOP than the wild-type-transfected cells. Because IL-6 is principally expressed following UPR induction (Fig. 5B) , these data indicate that HCV-induced UPR may be involved in the IFN resistance of core mutant clones.
DISCUSSION
In this study, we used a virus cell culture system to investigate the characteristics of R70Q, R70H, and L91M HCV core mutant viruses, which were clinically resistant to peg-IFN-plus-RBV treatment, and found that these core mutant clones showed resistance to IFN in vitro, consistent with the clinical findings (Fig. 1 ). These differences in the IFN sensitivity of the core mutant clones led us conduct a series of experiments to investigate the molecular mechanisms of IFN-related response pathways. We found that IFN-␣ receptor-mediated signaling was attenuated in wild-type HCV-infected and core mutantinfected cells compared to that in uninfected cells and that the suppression of IFN signaling was more potent for core mutant clones than for the wild type. The differences in the interferonmediated antiviral effects were demonstrated further by the difference in the induction rates of IFN-inducible P56, PKR, and 25AS mRNAs (Fig. 3A, B , and C) and IFN-induced phosphorylation of STAT1 and STAT2 ( Fig. 3D and E) . Furthermore, the expression levels of an interferon signal attenuator, SOCS3, were significantly higher in core mutant-transfected cells than in wild-type-transfected cells. Moreover, cellular expression of IL-6, which induces SOCS3 expression through phosphorylation of STAT3 (18, 41) , was significantly higher in the core mutant-transfected cells than in wild-type-transfected cells (Fig. 5A) . Taking all these things together, it is suggested strongly that the IFN resistance of core mutant clones is due to SOCS3-mediated attenuation of IFN responses and that, more importantly, upregulation of cellular IL-6 is attributable to emergence of IFN resistance (Fig. 7) . Miyanari et al. demonstrated that core protein, which is localized in LD-associated membrane, recruits HCV nonstructural (NS) proteins and replication complexes to LD and that this recruitment is critical for producing infectious viruses (35) . Furthermore, Masaki et al. reported that the NS5A protein interacts with core at its C-terminal serine cluster and this NS5A-core interaction is crucial for the production of virus particle (32) . In this study, there was no difference between the core mutants and the wild-type virus in terms of the pattern of colocalization of core protein with LDs and also the ER membrane (see the figure in the supplemental material). These results suggest that the core amino acid substitutions at positions 70 and 91 do not alter the characteristics of the core protein in terms of subcellular localization. Murray et al. conducted a comprehensive alanine substitution scan of the core protein to search for domains that are essential for virion production. They showed that substitutions of amino acids 70 and 91 spared but slightly decreased the capacity for virus particle production (37) , which is consistent with our present results. Those mutations may cause accumulation of virus and core protein in the LDs and ER membrane and may elicit UPRs and IFN resistance.
Type I IFNs and their responsive ISGs are the principal mediators of host defense against virus infections, including HCV (10, 26, 44) . Upon binding of IFNs to their receptors, IFNAR1 and IFNAR2, Janus kinases (Jak)1 and 2 phosphorylate STAT1 and STAT2 to form ISGF-3, which translocates to the nucleus and activates transcription of ISGs (46, 54, 55) . Members of the SOCS family are potent inhibitors of type I and type III IFN-induced activation of the Jak-STAT pathway and subsequent expression of ISGs (58) . HCV, on the other hand, counteracts such IFN-mediated antiviral pathways through its interaction with various steps of IFN signaling. The HCV NS5A and E2 proteins interfere with the action of IFN by inhibiting the activity of PKR (20, 56) . NS5A also induces expression of IL-8 and attenuates expression of ISGs (40) .
HCV core protein has been reported to interfere with the antiviral actions of IFN. Core protein binds the STAT1-SH domain (29) and destabilizes STAT1 (28) to block IFN signaling. Blindenbacher et al. (8) showed that STAT signaling was strongly inhibited in the hepatocytes of HCV core transgenic mice. Bode et al. showed that HCV core protein induced SOCS3 expression and inhibited tyrosine phosphorylation of STAT1 in HepG2 cells (9) . In this study, we used full-length HCV cell culture and found that SOCS3 expression is upregulated at different rates, depending on the genetic sequences of HCV strains, and that these differences in SOCS3 expression are associated with sensitivity to IFN. These results indicate that the IFN resistance of HCV-infected cells is mediated by overexpression of SOCS3, which may be upregulated by HCV proteins, as previously reported (9, 27) . Only one amino acid difference, R70Q, R70H, or L91M, might have affected cellular responses to interferon.
IL-6 is the principal activator of STAT3 in hepatocytes (18, 41) . It has been reported that plasma IL-6 levels are elevated in CHC patients (30) . Basu et al. have conducted DNA microarray analyses in HCV core-expressing cells and demonstrated that genes including those encoding IL-6 and STAT3 were upregulated by core protein (7) . Consistent with these findings, we found that cellular IL-6 expression levels were elevated in HCV-transfected cells in the order (from lowest to highest levels) untransfected, wild type, and then core mutants, which correlated well with SOCS3 expression (Fig. 4B) and with cellular responses to IFN (Fig. 1B and C) . The inducers of IL-6 remain to be clarified. IL-6 is secreted in response to cellular steatosis and insulin resistance (45) . Hepatic steatosis is found in 70% of CHC patients (57) and those with obesity; steatosis or insulin resistance is refractory to IFN treatment (43) . Such patients show higher levels of hepatic SOCS3 ex- pression than those without obesity or insulin resistance (34, 61) . We reported previously that a series of genes involved in fatty acid and cholesterol synthesis are upregulated in HCV replicon-expressing and HCV-JFH1-infected cells and increased cellular LDs (39) . Such lipogenic cellular processes may be the cause of the upregulated expression of IL-6. Alternatively, UPRs may produce IL-6. Chen et al. have reported that UPRs are coupled with TNF-␣ and IL-6 production in human macrophages (11) . In this study, transfection of Huh7 cells by HCV induced the expression of UPR genes, and their expression levels were significantly higher in mutant core protein-transfected cells than in wild type-transfected cells (Fig. 6 ).
The differences in ISG expression levels between the HCV wild type and core mutants were significant but small (Fig. 3A , B, and C). As shown in Fig. 3D , and E and 4B, the interclone differences in pSTAT and SOCS3 were significant but relatively small, which may explain the small differences in ISG levels. Similarly, the clinical difference in interferon treatment outcomes between core 70/91 mutants and wild types are significant but are around the sustained viral clearance rates of 32.4% versus 53.5% in core 70 or 91 mutants and wild types, respectively (19) , which might be consistent with our present results.
In clinical settings, IFN resistance of the core amino acid 70/91 mutants has been reported for genotype 1b strains (5). At present, there is no report that these mutations are associated with IFN treatment responses to other genotypes, including genotype 2a, which we used in this study. Because HCV strains other than genotypes 1 and 4 are generally sensitive to IFN, the core 70/91 mutations might not affect final treatment outcomes. We have conducted preliminary experiments using genotype 1b infectious clones with low levels of replication and found that these mutations did not significantly affect sensitivity to IFN in culture. It may be necessary to investigate IFN sensitivity when efficient cell culture systems have been developed for HCV genotype 1.
In addition to the poor virological responses of HCV core amino acid 70/91 mutants to peg-IFN-plus-RBV treatment (4, 6, 12) , patients infected with the core mutants showed increased incidence of hepatocellular malignancies (2, 15, 49) . It has been reported that the HCV core R70 but not L91 mutant frequently causes steatosis and increased hepatic oxidative stress (52) . It is possible that core 70/91 mutations not only induce IFN resistance but also may cause other pathophysiological conditions, such as carcinogenesis and disorders of lipid metabolism.
In conclusion, our study demonstrates that the IFN resistance of HCV core mutants may be, for the most part, determined by cellular expression levels of SOCS3 and IL-6. Therapeutic targeting of IL-6 potentially may be a key to targeting IFN resistance and improving antiviral chemotherapeutics against HCV.
